We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Simple Test Could Reduce Treatment of Bladder Cancer

By LabMedica International staff writers
Posted on 09 Jul 2018
Bladder cancer is relatively common and imposes the highest per patient cost on the healthcare system of the USA than the management of any other cancer type. More...
Most bladder cancers are early-stage tumors known as papillary non-muscle-invasive bladder cancer (NMIBC).

The decision whether to treat bladder cancer aggressively has been difficult as predictive diagnostic data is limited. Up to 70% of patients treated for early stage lesions that have not invaded the bladder wall will experience recurrence of these lesions, and 20% of these patients will develop an invasive cancer.

Scientists from the Georgetown University Medical Center (Washington, DC, USA) and their Danish counterparts initially evaluated in a cohort of 82 patients with papillary NMIBC (“Georgetown cohort”). Next, the value of Stromal Antigen 2 gene (STAG2) immunostaining for prediction of progression to muscle invasion was evaluated in a progressor-enriched cohort of 253 patients with papillary NMIBC (“Aarhus cohort”). The test involves examining bladder tumors that had been removed during initial surgery for over expression of the STAG2 gene.

In the Georgetown cohort, 52% of NMIBC tumors with intact STAG2 expression recurred, whereas 25% of STAG2-deficient tumors recurred. Multivariable analysis identified intact STAG2 expression as an independent predictor of recurrence. In the progressor-enriched Aarhus cohort, 38% of tumors with intact STAG2 expression progressed within five years, versus 16% of STAG2-deficient tumors. Multivariable analysis identified intact STAG2 expression as an independent predictor of progression. The authors stated that the test could, in some cases, spare patients constant surveillance and, in others, support forgoing aggressive treatment that can produce significant side effects.

Todd Waldman, MD, PhD, a professor of oncology and senior author of the study said, “We are closer to our goal of lowering the risk of both aggressive bladder cancer and over-surveillance and treatment side effects in bladder cancer patients. In principle, it might be possible to reduce the frequency of post-resection surveillance and therapy in patients whose cancer is STAG2-negative, and, conversely, treat patients and keep up high frequency surveillance in patients who have positive test results.” The study was published on June 28, 2018, in the journal Clinical Cancer Research.

Related Links:
Georgetown University Medical Center


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.